Semi-Solid Dosage Contract Manufacturing Market Report 2026

The semi-solid dosage contract manufacturing market size has grown rapidly in recent years. It will grow from $17.97 billion in 2025 to $19.89 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing pharmaceutical pipeline complexity, rising cost pressures on in-house manufacturing, expansion of topical and transdermal drug usage, growing demand for contract manufacturing services, availability of specialized cmo capabilities.

The semi-solid dosage contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $29.52 billion in 2030 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing demand for personalized topical therapies, rising investments in advanced formulation technologies, expansion of cosmeceutical outsourcing, growing focus on sustainable excipient usage, increasing regulatory scrutiny on manufacturing quality. Major trends in the forecast period include increasing outsourcing of semi-solid drug manufacturing, rising demand for specialized dermatological formulations, growing adoption of flexible manufacturing lines, expansion of bio-based and natural formulations, enhanced focus on regulatory-compliant production.

The high prevalence of skin diseases is expected to drive the growth of the semi-solid dosage contract manufacturing market going forward. Skin diseases refer to conditions that affect the skin’s appearance or function, often resulting in symptoms such as irritation, inflammation, or abnormal skin growths. The incidence of skin diseases is rising due to increasing environmental pollution, which compromises the skin’s natural defenses and leads to greater sensitivity, allergic reactions, and persistent dermatological issues. Contract manufacturing of semi-solid dosage forms supports the management of skin diseases by providing high-quality, consistently formulated topical treatments that help maintain and improve skin health. For instance, in February 2023, according to Cancer Research UK, a UK-based cancer research organization, the average annual incidence of melanoma skin cancer in the UK is projected to increase from approximately 20,800 cases in 2023-2025 to around 26,500 cases by 2038-2040. Therefore, the high prevalence of skin diseases is fueling the growth of the semi-solid dosage contract manufacturing market.

Key companies operating in the semi-solid dosage contract manufacturing market are focusing on strategic investments to enter new markets and drive innovation. Strategic investments refer to long-term financial initiatives made to support and strengthen a company’s core objectives, future growth, or competitive position. For example, in March 2025, LGM Pharma, a US-based provider of semi-solid dosage contract manufacturing services, announced an investment of over $6 million to expand its manufacturing facility in Rosenberg, Texas. The investment is intended to increase production capacity for liquid, suspension, semi-solid, and suppository drug formulations to meet growing domestic demand. It aligns with LGM Pharma’s ongoing expansion in prescription drug development, including 505(b)(2) and ANDA programs. Upgrades at the Rosenberg site will enable higher output while maintaining full compliance with FDA regulations and current good manufacturing practices, with operations continuing uninterrupted during expansion.

In June 2024, Aterian Investment Partners, a US-based private equity firm, acquired Contract Pharmaceuticals Limited Canada for an undisclosed amount. This acquisition positions CPL to enter a new phase of growth by strengthening capabilities in personnel, technology, and processes. The move enhances its ability to deliver greater value and maintain a strong position as a trusted provider to pharmaceutical companies worldwide. Contract Pharmaceuticals Limited is a Canada-based provider of semi-solid dosage contract manufacturing services.

Major companies operating in the semi-solid dosage contract manufacturing market are The Lubrizol Corporation, Recipharm AB, Piramal Pharma Solutions Inc., Cambrex Corporation, ANI Pharmaceuticals, Aurigene Pharmaceutical Services Limited, DPT Laboratories Ltd., Douglas Pharmaceuticals Ltd., Mission Pharmacal Co., Bora Pharmaceuticals Co. Ltd., Ascendia Pharmaceuticals Inc., Fermion Oy, Ferndale Pharma Group, Sterling Pharmaceutical Services LLC, Aphena Pharma Solutions Inc., Eubioco LLC, Madras Pharmaceuticals, Quality CDMO, Axxelent Pharma Science, Tergus Pharma, MedPharm Ltd., Alcami Corporation.

North America was the largest region in the semi-solid dosage contract manufacturing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the semi-solid dosage contract manufacturing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the semi-solid dosage contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the semi-solid dosage contract manufacturing market by increasing costs of imported excipients, processing equipment, mixing systems, packaging materials, and quality control instruments. Contract manufacturers in North America and Europe are most affected due to dependence on imported formulation inputs and machinery, while Asia-Pacific faces export cost pressures. These tariffs are raising production costs and influencing contract pricing structures. However, they are also encouraging local sourcing of raw materials, regional equipment manufacturing, and investment in cost-optimized and compliant domestic production facilities.

The semi-solid dosage contract manufacturing market research report is one of a series of new reports that provides semi-solid dosage contract manufacturing market statistics, including semi-solid dosage contract manufacturing industry global market size, regional shares, competitors with a semi-solid dosage contract manufacturing market share, detailed semi-solid dosage contract manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the semi-solid dosage contract manufacturing industry. This semi-solid dosage contract manufacturing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Semi-solid dosage contract manufacturing refers to a specialized pharmaceutical service in which a third-party manufacturer produces intermediate-consistency medicinal preparations on behalf of another company. This arrangement allows the contracting company to outsource production while focusing on core activities such as marketing or research.

The primary types of semi-solid dosage contract manufacturing include topical, transdermal, and oral formulations. Topical semi-solid manufacturing involves producing creams, gels, or ointments intended for direct application to the skin. These formulations use materials such as synthetic, natural, and bio-based ingredients and are utilized by companies of various sizes, including large, medium, and small enterprises. Applications include dermatology, pain management, hormonal therapy, wound care, ophthalmic disorders, and others, serving end users such as pharmaceutical companies, cosmeceutical companies, and others.

The semi-solid dosage contract manufacturing market consists of revenues earned by entities by providing services such as process development, formulation support, analytical method development, and quality control testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The semi-solid dosage contract manufacturing market also includes sales of medicated balms, moisturizing agents, lubricating agents, and skin repair agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.